Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - A simulation with the Diabetes Mellitus Model (DMM)

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 12, 2007, Pages 623-630

  Janka, H U ^a   Hessel, F ^b   Walzer, S ^c   Muller E ^c  

^a Klinikum Bremen Nord   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c Analytica International   (Germany)

Author keywords

Diabetes mellitus model; Insulin glargine; LAP; Premixed insulin; TOP study; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT DURATION; VASCULAR DISEASE;

ADULT; AGED; COMPUTER SIMULATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; SULFONYLUREA COMPOUNDS;

EID: 37349025812     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45623     Document Type: Article

References (22)

1. Bergemann R. Charakteristika valider Health-Outcomes-Modelle. Gesundheitsökonomie & Qualitätsmanagement. 2005; 10 (Suppl 2): 59-63.
2. Bergemann R, Hauner H, Morris AD, Dinneen SF, Suissa S, Gultyaev D, Maxion-Bergemann S, Müller E. Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mellitus Modell (DMM). Journal of Medical Economics. 2006; 9: 83-99.
3. Coyle D, Lee KM, O'Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. PharmacoEconomics. 2002; 20 (Suppl 1): 11-19.
4. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetes Medicine. 1999; 16: 716-730.
5. Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group. Glimepirid combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003; 138: 952-959.
6. Häring HU, Joost HG, Laube H, Matthaei S, Meissner HP, Panten U, Schernthaner G. Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenzbasierte Diabetes-Leitlinie DDG. Diabetes und Stoffwechsel. 2003; 12 (Suppl 2): 13-31.
7. Hauner H, Maxion-Bergemann S, Müller E, Schulz M, Huppertz E, Bergemann R. Disease Management Program (DMP) diabetes mellitus: simulation of therapeutic results of different guidelines. A new diabetes mellitus model. Dtsch Med Wochenschr. 2003; 128: 1167-1172.
8. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000; 23: 644-649.
9. Janka HU. Konventionelle und kombinierte Insulintherapie bei Typ-2-Diabetes. Diabetologe. 2006; 2: 304-313.
10. Janka HU, Hoegy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial and the German statutory health insurance (SHI). European Journal of Health Economics. 2007; DOI. 10.1007/s10198-007-0057-2.
11. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005; 28: 254-259.
12. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984; 102: 527-532.
13. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care. 1999; 22: 459-462.
14. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49:2142-2148.
15. Maxion-Bergemann S, Huppertz E, Jacobs LD, Müller E, Walleser S. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "Diabetes Mellitus Model". Int J Clin Pharmacol Ther. 2005; 43: 271-281.
16. Maxion-Bergemann S, Walleser S, Müller E, Dinneen SF, Suissa S, Hauner H, Morris AD, Bergemann R. Diabetes Mellitus Modell (DMM): internal validation of a computer simulation model for type 1 and type 2 diabetes. Journal of Medical Economics. 2006; 9: 69-82.
17. Raspe H, Sawicki P, Schmacke N. Sind vorliegende Disease-Management-Programme für Diabetes wirklich unnötig? Gesundheit, Gesellschaft, Wissenschaft. 2004; 4:23-31.
18. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412.
19. St. Vincent Declaration, Istanbul Commitment. 10th Anniversary of the St. Vincent Declaration Diabetes Action Program, Istanbul. 1999; In: Keen H. Therepeutic objectives and practical achievement in type 2 diabetes. J Diabetes Complications. 2000; 14:180-184.
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853 [Erratum (1999) Lancet 354: 602].
22. 1c control with BOT versus CT avoids long-term micro-vascular complications in patients with type-2-diabetes: model simulation with the DMM. ISPOR 9th Annual European Congress, Copenhagen, October 28th - 31st. Value in Health. 2006; 9/6: A223.